RNA Analysis Market Size to Hit Around USD 63.16 BN By 2032

The global RNA analysis market size was exhibited at USD 13.59 billion in 2022 and is projected to hit around USD 63.16 billion by 2032, growing at a CAGR of 16.61% during the forecast period 2023 to 2032.

Full Report is Ready | Download Free Sample Copy with TOC@ https://www.novaoneadvisor.com/report/sample/7592

Key Pointers:

• North America accounted for the largest share of more than 43.85% in 2022.?
• The real-time-PCR (qPCR) technology segment dominated the industry in 2022 and accounted for the maximum share of more than 44.09% of the global revenue.?
• The kits & reagents products segment dominated the global market in 2022 and accounted for the maximum share of more than 60.19% of the overall revenue.?
• The infectious diseases and pathogenesis application segment dominated the industry in 2022 and accounted for the largest share of more than 18.92% of the global revenue.?
• The government institutes & academic centers segment reported the highest revenue share of more than 33.09% in 2022.

Transcriptomics is one of the most advanced fields in the post-genomic period. Technological advancements in this industry can be attributed to the increasing applications of transcriptome sequencing in life science for capturing polyadenylated RNA. With the expansion of next-generation high-throughput sequencing technology, the analysis of transcriptomes has been gradually improving the understanding of the regulatory network of RNA-based genes. For instance, in July 2021, the Lithuanian team is developing a droplet-based technique for simultaneous mRNA and microRNA capture and sequencing in a single cell.

The research is backed by the European Union with a USD174,000 Horizon 2020 research grant. Moreover, in May 2022, CD Genomics launched the Digital RNA sequencing technology, which is an NGS-based method that excludes sequence-dependent PCR. Such initiatives are anticipated to accelerate market growth shortly. Ribonucleic acid transcriptome analysis enables the researchers to analyze the position of genes as well as the functional patterns of a specific gene in an organism. The method assists in evaluating every transcript’s changing behavior at the development stage and assesses all the elements of a transcript, including messenger ribonucleic acid, non-coding ribonucleic acid, and micro ribonucleic acid, for identifying the transcriptional structure of genes.

The growing need for analyzing a huge number of genes to understand the gene-to-drug interactions is anticipated to enhance the application of transcriptomics technologies in discovery applications and drug development. For instance, transcriptome profiles of COVID-19 patients have been analyzed to examine the disease prognosis and management. Furthermore, increasing demand for personalized medicines is anticipated to fuel the industry growth during the forecast period. In April 2020, Caris Life Sciences announced the submission of Pre-Market Approval applications for MI Transcriptome CDx to the USFDA. It is a powerful precision medicine assay, which contains significant companion diagnostic biomarkers. On the other hand, data management in transcriptomic research and the lack of effective bioinformatics tools are some of the major challenges in the industry.

The evolution of high-throughput technologies has provided invaluable opportunities for generating holistic views of complex biological processes. Despite the considerable availability of omics data, the conversation of biological data into clinically valuable knowledge remains one of the major challenges. It is not only because of insufficient current data processing or integration methods but also for inappropriate application of existing analysis approaches. North America has been reported as the highest revenue-generating region in 2021 owing to increasing investments in pharmaceutical and biotechnology research by corporations. Asia Pacific is projected to register the fastest CAGR from 2022 to 2030 owing to the low-cost manufacturing services.

Some of the prominent players in the RNA Analysis Market include:

• Agilent Technologies, Inc.
• F. Hoffmann-La Roche AG
• Illumina, Inc.
• QIAGEN
• Thermo Fisher Scientific, Inc.
• Eurofins Scientific
• Merck KGaA
• Bio-Rad Laboratories, Inc.
• Pacific Bioscience of California, Inc.
• Affymetrix, Inc.
• Danaher Corp.
• Promega

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global RNA Analysis market.

By Technology?

• Real Time-PCR (qPCR) Technology
• Microarray Technology
• Sequencing Technology
• Others

By Product?

• Instruments
• Kits & Reagents
• CHO Media miRNA & siRNA
• Reverse Transcriptases & RT-PCR
• RNA Extraction & Purification
• RNA Interference
• Others
• Services

By Application?

• Construction of RNA Expression Atlas
• Epigenetics
• Infectious Diseases&Pathogenesis
• Alternative RNA Splicing
• RNA Structure&Molecular Dynamics
• Development &Delivery of RNA Therapeutics
• Others

By End-use?

• Government Institutes & Academic Centers
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations (CROs)
• Hospitals & Clinics

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)

Full Report is Ready | Purchase This Premium Report Now@ https://www.novaoneadvisor.com/report/checkout/7592

You can place an order or ask any questions, please feel free to [email protected]| +1 9197 992 333

About US

Nova One Advisor is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Nova One Advisor has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.